申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:US10730830B2
公开(公告)日:2020-08-04
A compound of general formula (I-1):
wherein the symbols are defined in the specification, has a selective S1P5 receptor binding activity and modulates the function of an S1P5 receptor, and can therefore be a therapeutic agent for a S1P5-mediated disease, for example, neurodegenerative diseases such as schizophrenia, Binswanger's disease and the like.
通式(I-1)的化合物:
其中的符号在说明书中定义,具有选择性 S1P5 受体结合活性并调节 S1P5 受体的功能,因此可作为 S1P5 介导的疾病(例如精神分裂症、宾斯旺格病等神经退行性疾病)的治疗剂。